Pembrolizumab biosimilar (PlantForm/PlantPraxis)

N/A

Report date: 2025/03/07 17:33:48

Base Information

Drug NamePembrolizumab biosimilar (PlantForm/PlantPraxis)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPlantForm CorpPlantPraxis Biotecnologia Ltda
China Registration ClassN/A

Develop Information

Active CompaniesPlantForm CorpBio-Manguinhos
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A